24515-53-5

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl N-chloroacetylsarcosinate is used as an intermediate in the synthesis of various pharmaceuticals for its ability to undergo esterification, amidation, and nucleophilic substitution reactions. These reactions allow for the creation of biologically active molecules with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, ethyl N-chloroacetylsarcosinate serves as a key intermediate in the production of various agrochemicals. Its versatility in organic synthesis enables the development of compounds with pesticidal or herbicidal properties, contributing to crop protection and yield enhancement.
Used in Materials Science:
Ethyl N-chloroacetylsarcosinate is utilized in materials science for the synthesis of novel materials with specific properties. Its ability to participate in various chemical reactions allows for the creation of materials with potential applications in different fields, such as polymers, coatings, or adhesives.
Used in Organic Synthesis:
As a versatile building block, ethyl N-chloroacetylsarcosinate is used in organic synthesis for the preparation of a wide range of compounds. Its reactivity in esterification, amidation, and nucleophilic substitution reactions makes it a valuable component in the synthesis of complex organic molecules for various applications.

Upstream product

• 52605-49-9 sarcosine ethyl ester hydrochloride 
• 79-04-9 chloroacetyl chloride 
• 13200-60-7 Sarcosine ethyl ester 

Downstream Products

• 5625-52-5 1-methylpiperazin-2,5-dione 
• 1261491-89-7 2-((2-ethoxy-2-oxoethyl)(methylamino)-2-oxoethyl 5-tetradecyloxy)furan-2-carboxylate 
• 116482-77-0 2-Acetoxy-benzoic acid (ethoxycarbonylmethyl-methyl-carbamoyl)-methyl ester 
• 106231-63-4 2-(benzoyloxy)-(N-methyl-N-ethoxycarbonylmethyl)acetamide 

Relevant academic research and scientific papers

PYRROLE DERIVATIVES AS ACC INHIBITORS

Novel pyrrole derivatives of Formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Acetyl- CoA carboxylase (ACC).

DRUGS TO TREAT OCULAR DISORDERS

The present invention provides new prodrugs of therapeutically active loop diuretics, including oligomeric prodrugs, and compositions to treat medical disorders, for example, ocular disorders such as glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention include substituted Lanicemine prodrugs useful for the treatment of conditions associated with dysregulation of NMDA receptor activity such as depression and depressive disordersthrough the release of Lanicemine, Prodrugs of Lanicemine have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release Lanicemine in the plasma via either an enzymatic or general biophysical release process.

DERMATOLOGICAL FORMULATIONS OF 2-(2-ETHOXY-2-OXOETHYL)(METHYL)AMINO-2-OXOETHYL 5-(TETRADECYLOXY)FURAN-2-CARBOXYLATE

Disclosed herein are dermatological formulations comprising low-impurity TOFA prodrug 2-(2-ethoxy-2-oxoethyl)(methyl)amino-2-oxoethyl 5-(tetradecyloxy)furan-2-carboxylate represented by Formula (la) and pharmaceutical use thereof.

Olumacostat glasaretil

Acne vulgaris is a common dermatologic condition affecting adolescents and adults. Systemic and topical therapies have been developed to target different mechanisms in the pathogenesis of acne. Olumacostat glasaretil (OG) is a novel topical agent that targets sebum production in the treatment of acne vulgaris. OG’s active metabolite acts as a competitive inhibitor of the rate-limiting enzyme of fatty acid synthesis, acetyl-coenzyme A (CoA) carboxylase (ACC). ACC catalyzes malonyl-CoA formation and sebum production. OG is efficacious in the treatment of acne vulgaris and has a low side effect profile. Phase IIa and IIb trials note side effects including application-site erythema and dryness, and nasopharyngitis. Phase III trials are currently underway. The new mechanism of action of OG is sensible, attractive and exciting, but the available data do not demonstrate that it provides a quantum leap forward over existing therapies.

SYNTHETIC PROCESS FOR PREPARING 2-((2-ETHOXY-2-OXOETHYL)(METHYL)AMINO)-2-OXOETHYL 5-TETRADECYLOXY)FURAN-2-CARBOXYLATE

Disclosed herein are processes for forming 2-((2-ethoxy-2-oxoethyl)(methyl)amino)-2-oxoethyl 5-tetradecyloxy)furan-2-carboxylate:

Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs

A series of glycolamide, glycolate, (acyloxy)methyl, alkyl, and aryl esters of acetylsalicylic acid (aspirin) were synthesized and evaluated as potential prodrug forms of aspirin. N,N-Disubstituted glycolamide esters were found to be rapidly hydrolized in human plasma, resulting in the formation of aspirin as well as the corresponding salicylate esters. These in turn hydrolyzed rapidly to salicylic acid. The largest amount of aspirin formed from the esters were 50 and 55% in case of the N,N-dimethyl- and N,N-diethylglycolamide esters, respectively. Similar results were obtained in blood with the N,N-dimethyl- and N,N-diethylglycolamide esters. Unsubstituted and monosubstituted glycolamide esters as well as most other esters previously suggested to be aspirin prodrugs were shown to hydrolyze exclusively to the corresponding salicylic acid esters. Lipophilicity parameters and water solubilities of the esters were determined, and structural factors favoring ester prodrug hydrolysis at the expense of deacetylation to yield salicylate ester are discussed. The properties of some N,N-disubstituted glycolamide esters of aspirin are highlighted with respect to their use as potential aspirin prodrugs.

An Improved Synthesis of 1-Methyl-2,5-piperazinedione

A new synthesis of 1-methyl-2,5-piperazinedione in three steps starting from sarcosine is described.This method proceeds in higher overall yield (49 percent) than previous methods.